SYNDAX PHARMACEUTICALS INC SNDX Income Statement

Syndax pharmaceuticals inc (SNDX)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15
Revenue:
Total revenues
1,517	1,517	1,517	1,517	1,517	1,517	2,330	2,256	2,182	2,108	0	0	0	-	-	-	-	-	-	-	-
Total revenues
1,517	1,517	1,517	1,517	1,517	1,517	2,330	2,256	2,182	2,108	0	0	0	-	-	-	-	-	-	-	-
License fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,220	932	0	-	0	0	-
Total revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,220	932	0	-	0	0	-
Operating expenses:
Research and development
41,277	42,994	49,313	53,485	56,046	60,106	60,884	58,977	53,988	48,201	40,076	40,162	36,431	31,665	25,778	16,472	12,612	9,549	0	0	0
General and administrative
18,068	16,062	14,871	15,391	16,407	17,287	17,478	16,916	16,722	15,861	14,750	14,456	12,979	13,321	12,746	12,672	13,152	11,591	0	0	0
Total operating expenses
59,345	59,056	64,184	68,876	72,453	77,393	78,362	75,893	70,710	64,062	54,826	54,618	49,410	44,986	38,524	29,144	25,764	21,140	0	0	0
Loss from operations
-57,828	-57,539	-62,667	-67,359	-70,936	-75,876	-76,032	-73,637	-68,528	-61,954	-53,606	-53,398	-48,190	-43,766	-37,304	-27,924	-24,832	-20,513	0	0	0
Other (expense) income:
Interest expense
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	956	164	-333	-931	-1,414	0	0	0
Change in fair value of common stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	1,703	1,773	3,380	3,726	2,155	0	0	0
Other (expense) income
-156	-79	0	0	0	-	-	-	-	-	-	-	-	41	-7	-45	-49	-37	0	0	0
Total other (expense) income
847	1,492	1,783	1,966	2,071	1,915	1,804	1,659	1,299	1,152	1,093	1,004	1,077	-706	-1,616	-3,758	-4,706	-3,606	0	0	0
Net loss
-56,981	-56,047	-60,884	-65,393	-68,865	-73,961	-74,228	-71,978	-67,229	-60,802	-52,513	-52,394	-47,113	-44,472	-38,920	-31,682	-29,538	-24,119	0	0	0
Other comprehensive income (loss):
Unrealized gain on marketable securities
0	-	0	0	0	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0
Comprehensive loss
0	-	0	0	0	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0
Net loss attributable to common stockholders
-60,887	-56,047	0	0	0	-	-	-	-	-	-	-	-	-47,070	-45,034	-86,721	-104,701	-103,845	0	0	0
Net loss per share attributable to common stockholders—basic and diluted
-0.56	-0.44	-0.41	-0.47	-0.53	0.70	0.68	0.74	0.79	-0.80	-0.84	-0.47	-2.85	0.94	-0.84	-0.47	-2.85	-81.60	-790.85	-440.52	-206.30
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—basic and diluted
34,328	31,640	31,630	31,605	27,023	26,804	25,471	24,705	24,478	23,943	22,239	19,497	18,231	18,268	17,899	17,769	4,541	83	71	59	58